Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 4
1(25.0%)
4Total
Phase 2(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04105231Phase 2Active Not Recruiting

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

Role: lead

NCT06062953Phase 2Recruiting

Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia

Role: lead

NCT06752616Phase 2Recruiting

Acute Agitation in Emergency Psychiatry

Role: lead

NCT01431092Phase 4Completed

Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia

Role: lead

All 4 trials loaded